NASDAQ · BDSX
Biodesix, Inc.
$24.72+$1.86 (+8.14%)
Biodesix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.68% below the high.
Loading market information…
NASDAQ · NOTV · USD
Stock price, earnings
Quote as of Jun 10, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Inotiv, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Inotiv, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company’s BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:21 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Dec 3, 2024 | -$0.16+82.42% vs estimate | $130.42M+11.53% vs estimate |
|---|
| Q3 2024 | Aug 8, 2024 | -$1.00-1,011.11% vs estimate | $105.79M-14.27% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$24.72+$1.86 (+8.14%)
Biodesix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.68% below the high.
$0.73+$0.01 (+1.67%)
Rein Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$7.29$0.00 (0.0%)
Kezar Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.44% below the high.
$9.07-$0.15 (-1.63%)
FibroGen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.68% below the high.
$9.81-$0.07 (-0.71%)
Star Equity Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 17.63% below the high.
$0.54+$0.01 (+1.34%)
HeartBeam, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.53% below the high.
$0.85-$0.09 (-9.66%)
Celularity Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.69% below the high.
$3.03-$0.11 (-3.5%)
bioAffinity Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.25% below the high.
